Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

329

HTML

2943

Figures (1-2)

171

Tables (1-4)

136

Sum=3579

Nov 21, 2012 (publication date) through Jul 18, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 21, 2012; 18(43): 6277-6283
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6277

Table 1 Baseline characteristics of the study population

Baseline characteristics	Total (n = 48)
Age, yr (mean ± SD)	42.1 ± 12.9
Sex (male/female)	29/19
Pretreatment ALT level (IU/L)	198 (11-374)
Pretreatment HBV DNA level (log₁₀ copies/mL)	8.5 (5.0-10)
Time to undetectable HBV (mo)	7.7 (1.3-39.4)
Time to HBeAg seroconversion (mo)	13.4 (0.8-39.4)
Consolidation treatment duration (mo)	10.3 (6-37.9)
Total treatment duration (mo)	26.1 (9.4-47.4)
Antiviral agent (entecavir/clevudine)	31/17
Previous NUC treatment (naïve/lamivudine)	41/7

ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; NUC: Nucleos(t)ide analogues.

Citation: Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283
URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6277.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i43.6277